Neurocrine Biosciences (NASDAQ:NBIX) Given New $220.00 Price Target at TD Cowen

01 Aug 2026, 05:51 by Scott Moore · The Cerbat Gem

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price target increased by TD Cowen from $200.00 to $220.00 in a research report released on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Several other research firms have also issued reports on NBIX. Morgan Stanley upped their price target on shares of Neurocrine Biosciences from $185.00 to $191.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Guggenheim lifted their price objective on shares of Neurocrine Biosciences from $200.00 to $222.00 and gave the company a “buy” rating in a research report on Friday. Weiss Ratings upgraded shares of Neurocrine Biosciences from a “buy (b-)” rating to a “buy (b)” rating in a research note on Tuesday. Wall Street Zen upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 25th. Finally, Piper Sandler upped their target price on shares of Neurocrine Biosciences from $207.00 to $210.00 and gave the company an “overweight” rating in a report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $199.64.

Get Our Latest Research Report on NBIX

Neurocrine Biosciences Trading Down 10.1%

NASDAQ NBIX opened at $166.80 on Friday. Neurocrine Biosciences has a 12 month low of $122.14 and a 12 month high of $186.12. The stock has a 50 day moving average of $167.81 and a 200-day moving average of $146.40. The company has a market cap of $16.77 billion, a PE ratio of 24.46, a PEG ratio of 0.78 and a beta of 0.39.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Julie Cooke sold 36,937 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $156.22, for a total transaction of $5,770,298.14. Following the completion of the sale, the insider owned 22,374 shares of the company’s stock, valued at $3,495,266.28. This trade represents a 62.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard F. Pops sold 15,000 shares of Neurocrine Biosciences stock in a transaction on Friday, May 15th. The stock was sold at an average price of $157.65, for a total transaction of $2,364,750.00. Following the transaction, the director directly owned 34,480 shares of the company’s stock, valued at approximately $5,435,772. This trade represents a 30.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 395,422 shares of company stock worth $62,448,693 in the last three months. 4.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Neurocrine Biosciences

Large investors have recently modified their holdings of the stock. Generali Investments Management Co LLC lifted its stake in shares of Neurocrine Biosciences by 19.8% during the 2nd quarter. Generali Investments Management Co LLC now owns 10,644 shares of the company’s stock worth $1,794,000 after buying an additional 1,762 shares during the last quarter. Handelsbanken Fonder AB boosted its holdings in shares of Neurocrine Biosciences by 9.6% during the 2nd quarter. Handelsbanken Fonder AB now owns 205,871 shares of the company’s stock worth $34,696,000 after buying an additional 18,004 shares during the period. Fulton Bank N.A. grew its stake in Neurocrine Biosciences by 5.2% in the 2nd quarter. Fulton Bank N.A. now owns 4,895 shares of the company’s stock valued at $825,000 after buying an additional 243 shares during the last quarter. Valeo Financial Advisors LLC acquired a new position in Neurocrine Biosciences in the 2nd quarter valued at about $283,000. Finally, Trust Point Inc. acquired a new position in Neurocrine Biosciences in the 2nd quarter valued at about $245,000. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences News Roundup

Here are the key news stories impacting Neurocrine Biosciences this week:

Positive Sentiment: Strong Q2 performance: Second-quarter revenue rose 39% year over year to $959 million, exceeding the approximately $891 million analyst estimate. Adjusted earnings were $2.85 per share versus the $2.26 consensus, while net income increased to $144.4 million. Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
Positive Sentiment: Product and pipeline growth: INGREZZA sales increased 15% to $716 million, while CRENESSITY generated $184 million and newly acquired VYKAT XR contributed $54 million. Neurocrine also raised its 2026 INGREZZA sales guidance to $2.825 billion-$2.875 billion, supporting the company’s commercial outlook and Soleno Therapeutics acquisition. NBIX Q2 Earnings Call Highlights
Positive Sentiment: Analyst support strengthened: TD Cowen, Guggenheim, Stifel, Cantor Fitzgerald, Piper Sandler, Needham, RBC and Morgan Stanley all raised their price targets, with targets ranging from $196 to $222. William Blair also reiterated a Buy rating, citing strong execution and substantial pipeline potential. Analyst Price Target Updates
Neutral Sentiment: Investor expectations remain elevated: Although NBIX beat quarterly estimates, the market appears to have wanted a larger revenue upside surprise or more aggressive full-year guidance. The reaction suggests investors may be reassessing how much near-term upside is already reflected in the shares.
Negative Sentiment: Insider selling adds a cautionary signal: Director Leslie Norwalk sold 1,250 shares for about $228,000 under a pre-arranged Rule 10b5-1 plan. Broader data also show numerous insider sales and no open-market purchases over the past six months, though such transactions may be planned and do not necessarily indicate deteriorating fundamentals. SEC Insider Trading Filing

About Neurocrine Biosciences

(Get Free Report)

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.